Verastem reports cancer-drug data, prices offering and names CEO successor
Verastem Oncology reported Phase 1/2 results for its VS-7375 cancer candidate on October 14, 2026, including a 41% objective response rate in pancreatic cancer and a confirmed 43% rate in non-small cell lung cancer. It priced an offering of 30,937,500 common shares at $8.00 each and pre-funded warrants for 312,503 shares at $7.9999 each, with approximately $250 million in gross proceeds expected and closing targeted for October 15, 2026. Michael P. Bailey is set to become president and CEO on January 1, 2027, and the company plans a Phase 3 pancreatic cancer trial by the end of 2026.
Why it matters
The financing would provide Verastem with capital for VS-7375 development, working capital and general corporate purposes, while adding common shares and potential warrant dilution if completed. The reported trial results and planned Phase 3 study mark the candidate's next development steps, and the CEO transition changes leadership from January 2027.
Key facts
- 1In the pancreatic cancer cohort, VS-7375 produced an 86% disease control rate, with six-month landmark progression-free survival and overall survival rates of 67% and 80%, respectively. rttnews.com
- 2In colorectal cancer, VS-7375 combined with an anti-EGFR therapy produced a 33% objective response rate among six patients. rttnews.com
- 3Verastem plans to start a Phase 3 trial in first-line metastatic pancreatic cancer by the end of 2026 after discussions with the U.S. Food and Drug Administration. rttnews.com
- 4Michael P. Bailey will succeed Daniel Paterson, who will continue as an advisor and board member. rttnews.com
- 5At the 900 mg dose, adverse events caused treatment discontinuation in 2% of patients, with gastrointestinal effects primarily low grade. rttnews.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.